Surgalign Holdings, Inc.

Industry

  • Biotechnology
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
    • Implantable Devices
    • Biomaterials
  • Digital Health
    • Artificial Intelligence

Other Names/Subsidiaries

  • Paradigm Spine, LLC
  • Regeneration Technologies, Inc.
  • Tutogen Medical, Inc.
  • Pioneer Surgical Technology, Inc.
  • RTI Biologics, Inc.
  • Zyga Technology
  • RTI Surgical, Inc.
See more in Biomedtracker

Latest on Surgalign Holdings, Inc.

Medtech Insight

Market Brief: Global Orthobiologics Market Will Reach $2.3Bn By 2023 With Highest Growth In Cartilage Replacement

 
• By Marion Webb

The global market for orthobiologics for musculoskeletal soft tissue replacement and regeneration is expected to reach $2.3bn by 2023, with a compound annual growth rate (CAGR) of 4.0%, according to "

In Vivo

Deals Shaping The Medical Industry, February 2018

 
• By Beth Allan, Deanna Kamienski, and Maureen Riordan

IN VITRO DIAGNOSTICS Financings HTG Molecular Diagnostics Inc. HTG Molecular Diagnostics Inc. netted $37.9mm through a public offering of 13.9mm common shares (including the overallotment) at $2.9

In Vivo

Deals Shaping The Medical Industry, September 2017

 
• By Beth Allan, Deanna Kamienski, Maureen Riordan, Steven Muntner, and Amanda Micklus

IN VITRO DIAGNOSTICS Financings Cancer Genetics Inc. Molecular diagnostics firm Cancer Genetics Inc. entered a financing agreement with Aspire Capital, through which Aspire will purchase, over the

Medtech Insight

Market Intel: Orthobiologics Market Well-Positioned For Innovative Reconstruction

 
• By Gayle Grimes

The global market for orthobiologic products used in musculoskeletal soft tissue replacement and regeneration is expected to expand at a compound annual growth rate of 5.9% to reach $1.4bn by 2021. Ac